Seres Therapeutics Inc. (NASDAQ:MCRB) price closed lower on Monday, September 13, dropping -6.06% below its previous close.
A look at the daily price movement shows that the last close reads $6.27, with intraday deals fluctuated between $5.69 and $6.4499. The company’s 5Y monthly beta was ticking 3.96. Taking into account the 52-week price action we note that the stock hit a 52-week high of $38.50 and 52-week low of $5.80. The stock subtracted -13.38% on its value in the past month.
Seres Therapeutics Inc., which has a market valuation of $523.80 million, is expected to release its quarterly earnings report Nov 08, 2021 – Nov 12, 2021. Analysts tracking MCRB have forecast the quarterly EPS to shrink by -0.46 per share this quarter, while the same analysts predict the annual EPS to hit -$1.86 for the year 2021 and up to -$1.36 for 2022. In this case, analysts estimate an annual EPS growth of -66.10% for the year and 26.90% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $7.32 million, with the likely lows of $5 million and highs of $12.18 million. Staying with the analyst view, there is a consensus estimate of $25.57 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -23.00% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give MCRB a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 9 analysts have assigned MCRB a recommendation rating as follows: 1 rate it as a Hold; 7 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Seres Therapeutics Inc. (MCRB) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that MCRB’s price is at present -7.46% off the SMA20 and -44.67% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 29.25, with weekly volatility standing at 8.51%. The indicator jumps to 6.12% when calculated based on the past 30 days. Seres Therapeutics Inc. (NASDAQ:MCRB)’s beta value is holding at 3.98, while the average true range (ATR) indicator is currently reading 0.39. Considering analysts have assigned the stock a price target range of $7.00-$32.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $20.57. Based on this estimate, we see that current price is roughly -18.85% off the estimated low and -443.29% off the forecast high. Investors will no doubt be excited to see the share price fall to $19.00, which is the median consensus price, and at that level MCRB would be -222.58% from current price.
Turning out attention to how the Seres Therapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: MCRB’s stock is -6.06% on the day and -76.90% in the past 12 months, while Acceleron Pharma Inc. (XLRN) traded 0.11% in the last session and was positioned 46.68% up on its price 12 months ago. Another comparison is with Xencor Inc. (XNCR) whose stock price was up 1.84% in the last trading session, and has flourished -12.69% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.
An analysis of the Seres Therapeutics Inc. (NASDAQ:MCRB) stock in terms of its daily trading volume indicates that the 3-month average is 1.78 million.
Current records show that the company has 91.66M in outstanding shares. The insiders’ percentage holdings are 9.06% of outstanding shares while the percentage share held by institutions stands at 90.50%. But the -75.96% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.